Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial
OPEN Circulation | 13 Mar 2016
MD Dake, GM Ansel, MR Jaff, T Ohki, RR Saxon, HB Smouse, LS Machan, SA Snyder, EE O'Leary, AO Ragheb and T Zeller
-This randomized controlled trial (RCT) evaluated clinical durability of Zilver PTX, a paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes compare primary DES versus percutaneous transluminal angioplasty (PTA); overall DES (primary and provisional) versus standard care (PTA and provisional Zilver bare metal stent [BMS]); and provisional DES versus provisional BMS.
* Data courtesy of Altmetric.com